TP53 mutations and RNA-binding protein MUSASHI-2 drive resistance to PRMT5-targeted therapy in B-cell lymphoma. - Erazo T; Evans CM; Zakheim D; Chu EL; Refermat AY; Asgari Z; Yang X; Da Silva Ferreira M; Mehta S; Russo MV; Knezevic A; Zhang XP; et al. (Nature communications, 2022)